




# PHARMACEUTICAL 2022

iBio Inc.  
Rank 179 of 466





# PHARMACEUTICAL 2022

iBio Inc.  
Rank 179 of 466



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 98% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	104,597
Cost of Goods Sold	1,462
Intangible Assets	952
Liabilities, Current	6,645
Liabilities, Non-Current	0
Other Assets	32,791
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	31,755
Other Net Income	7,898
Other Revenues	2,371
Property and Equipment	8,628
Research and Development	9,989
Selling, General and Administrative Expense	22,031

Output Variable	Value in 1000 USD
Assets	146,968
Liabilities	38,400
Expenses	33,482
Revenues	2,371
Stockholders Equity	108,568
Net Income	-23,213
Comprehensive Net Income	-23,213
Economic Capital Ratio	176%